At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 46 enrolled
Drug / intervention
diacerein 1% ointmentdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 21-Day, Randomized, Controlled Study to Evaluate the Skin Irritation Potential of CCP-020 (Diacerein 1%) Topical Ointment in Healthy Subjects Using a Cumulative Irritant Patch Test Design
In Brief
A Phase 1 clinical trial evaluating diacerein 1% ointment for Healthy. Completed, enrolled 46 participants across 1 site.
Detailed Summary
Single center, randomized, controlled, evaluator blinded, within-subject study to evaluate the irritation potential of diacerein1% ointment on normal skin of healthy volunteers, using a cumulative irritancy patch test (CIPT) procedure.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
CollaboratorsTKL Research, Inc.
Timeline
Phase 1CompletedFinished
201820192020202120222023202420252026
Enrollment StartJan 2018
Primary CompletionJan 2018
First PostedMar 2018
TodayJul 2026
First PostedMar 21, 2018
Enrollment StartJan 9, 2018
Primary CompletionJan 30, 2018
TodayJul 2, 2026
Enrollment to primary: 21 daysPosted 8.3 years ago
Interventions
diacerein 1% ointmentdrug
diacerein 1% ointment applied to the skin of the infrascapular area of the back under occlusive patch for 21 days.